KRAS and pancreatic adenocarcinoma: Activating mutations of KRAS are detected in over 95% of human pancreatic adenocarcinoma (PDA)1; and genetic mouse models have demonstrated that acquisition of oncogenic KRas is an initial event leading to pancreatic cancer2.